Stephen Andrews, MD
Gynecologic Oncology · Akron, OHNPI 1255328845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 87 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$406
- Eisai Inc.$294
- Clovis Oncology, Inc.$270
- Genmab U.S., Inc.$207
- AbbVie$98
- GSK$95
- plus $420 from 10 others
Across 7 payments — averaging $3093.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$22K
What the payments were for
- Food & beverage$1,69194%
- Education$996%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $406 |
| Eisai Inc. | 13 | $294 |
| Clovis Oncology, Inc. | 18 | $270 |
| Genmab U.S., Inc. | 11 | $207 |
| AbbVie | 4 | $98 |
| GSK | 4 | $95 |
| AstraZeneca | 4 | $82 |
| Tempus AI, Inc | 3 | $78 |
| Myriad Genetic Laboratories, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 3 | $58 |
| Tesaro, Inc. | 1 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Meditrina | 1 | $10 |
How this compares
$1,790 in reported general payments places this provider in the 55th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 29 | $1,346 |
| Clobetasol Propionate | 22 | $505 |
| Megestrol Acetate | 15 | $406 |
| Prochlorperazine Maleate | 36 | $396 |
| Gabapentin | 11 | $135 |
| Oxycodone Hcl | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Akron
- Robin Laskey-JobkarAkron$1K
- Tara DonaldsonAkron$395
- Jodi ReganAkron$208
- Michael HopkinsAkron$154
- David OmalleyHilliard$650K
- Thomas HerzogCincinnati$585K
- Floortje BackesHilliard$181K
- Adam WalterSylvania$137K
- Amanda JacksonCincinnati$92K
- Amelia JerniganCleveland$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.